BTIG analyst Ryan Zimmerman maintained a Buy rating on Electrocore (ECOR) yesterday and set a price target of $3.50. The company’s shares closed last Thursday at $1.66.
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 14.0% and a 60.1% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Electrocore with a $3.17 average price target.
See today’s analyst top recommended stocks >>
Based on Electrocore’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $753K and GAAP net loss of $4.74 million. In comparison, last year the company earned revenue of $622.7K and had a GAAP net loss of $12.1 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.
